Endo eyes a deal for Somerset and Wintac
Endo is set to augment the firm’s commercial portfolio and pipeline of generic sterile injectables and ophthalmic drugs, as well as bolster its manufacturing capabilities, after agreeing to acquire New Jersey based Somerset Therapeutics and its contract development and manufacturing business, India’s Wintac, for around US$190 million.
You may also be interested in...
Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.